Cerebrospinal fluid biomarkers and cognitive status in differential diagnosis of frontotemporal dementia and Alzheimer’s disease

Research output: Contribution to journalArticle

Abstract

Objective: This study aimed to determine the most appropriate cognitive and cerebrospinal fluid (CSF) biomarker setting to distinguish frontotemporal dementia (FTD) from Alzheimer’s disease (AD). Method: Patients with FTD, those with AD, and those without dementia were enrolled in this study. CSF amyloid-ß 42 (Aß42), total (t)-tau, and phosphorylated (p)-tau concentrations were determined by enzyme-linked immunosorbent assays. Cognition was evaluated by the Mini-Mental State Examination (MMSE) and its domain scores. The associations of CSF biomarkers with cognitive measures were examined using regression models and the diagnostic value of CSF biomarkers was determined by receiver operating characteristics curves. Results: CSF Aß42 levels were lower, whereas t-tau/Aß42 and p-tau/Aß42 ratios were higher in patients with AD compared with those with FTD. Some MMSE domain scores were different in FTD and AD, but they did not improve the ability to distinguish between the two pathologies. Poor temporal orientation scores were associated with low Aß42 levels only in patients with FTD. The p-tau/Aß42 ratio reached sufficient levels of sensitivity and specificity to discriminate FTD with primary progressive aphasia from AD. Conclusions: The ratio of CSF p-tau/Aß42 is a sensitive and specific biomarker for discriminating patients with primary progressive aphasia from those with AD.

Original languageEnglish
Pages (from-to)4968-4980
Number of pages13
JournalJournal of International Medical Research
Volume47
Issue number10
DOIs
Publication statusPublished - Oct 1 2019

Fingerprint

Cerebrospinal fluid
Frontotemporal Dementia
Biomarkers
Amyloid
Cerebrospinal Fluid
Alzheimer Disease
Differential Diagnosis
Primary Progressive Aphasia
Immunosorbents
Aptitude
Pathology
ROC Curve
Cognition
Dementia
Assays
Enzyme-Linked Immunosorbent Assay
Regression Analysis
Sensitivity and Specificity
Enzymes

Keywords

  • Alzheimer’s disease
  • biomarker
  • cerebrospinal fluid
  • frontotemporal dementia
  • Mini-Mental State Examination
  • p-tau/Aß42 ratio

ASJC Scopus subject areas

  • Biochemistry
  • Cell Biology
  • Biochemistry, medical

Cite this

@article{5935ced514fd4e5ca41a1511723c8aec,
title = "Cerebrospinal fluid biomarkers and cognitive status in differential diagnosis of frontotemporal dementia and Alzheimer’s disease",
abstract = "Objective: This study aimed to determine the most appropriate cognitive and cerebrospinal fluid (CSF) biomarker setting to distinguish frontotemporal dementia (FTD) from Alzheimer’s disease (AD). Method: Patients with FTD, those with AD, and those without dementia were enrolled in this study. CSF amyloid-{\ss} 42 (A{\ss}42), total (t)-tau, and phosphorylated (p)-tau concentrations were determined by enzyme-linked immunosorbent assays. Cognition was evaluated by the Mini-Mental State Examination (MMSE) and its domain scores. The associations of CSF biomarkers with cognitive measures were examined using regression models and the diagnostic value of CSF biomarkers was determined by receiver operating characteristics curves. Results: CSF A{\ss}42 levels were lower, whereas t-tau/A{\ss}42 and p-tau/A{\ss}42 ratios were higher in patients with AD compared with those with FTD. Some MMSE domain scores were different in FTD and AD, but they did not improve the ability to distinguish between the two pathologies. Poor temporal orientation scores were associated with low A{\ss}42 levels only in patients with FTD. The p-tau/A{\ss}42 ratio reached sufficient levels of sensitivity and specificity to discriminate FTD with primary progressive aphasia from AD. Conclusions: The ratio of CSF p-tau/A{\ss}42 is a sensitive and specific biomarker for discriminating patients with primary progressive aphasia from those with AD.",
keywords = "Alzheimer’s disease, biomarker, cerebrospinal fluid, frontotemporal dementia, Mini-Mental State Examination, p-tau/A{\ss}42 ratio",
author = "Tiziana Casoli and Susy Paolini and Paolo Fabbietti and Patrizia Fattoretti and Lucia Paciaroni and Katia Fabi and Beatrice Gobbi and Roberta Galeazzi and Roberto Rossi and Fabrizia Lattanzio and Giuseppe Pelliccioni",
year = "2019",
month = "10",
day = "1",
doi = "10.1177/0300060519860951",
language = "English",
volume = "47",
pages = "4968--4980",
journal = "Journal of International Medical Research",
issn = "0300-0605",
publisher = "Field House Publishing LLP",
number = "10",

}

TY - JOUR

T1 - Cerebrospinal fluid biomarkers and cognitive status in differential diagnosis of frontotemporal dementia and Alzheimer’s disease

AU - Casoli, Tiziana

AU - Paolini, Susy

AU - Fabbietti, Paolo

AU - Fattoretti, Patrizia

AU - Paciaroni, Lucia

AU - Fabi, Katia

AU - Gobbi, Beatrice

AU - Galeazzi, Roberta

AU - Rossi, Roberto

AU - Lattanzio, Fabrizia

AU - Pelliccioni, Giuseppe

PY - 2019/10/1

Y1 - 2019/10/1

N2 - Objective: This study aimed to determine the most appropriate cognitive and cerebrospinal fluid (CSF) biomarker setting to distinguish frontotemporal dementia (FTD) from Alzheimer’s disease (AD). Method: Patients with FTD, those with AD, and those without dementia were enrolled in this study. CSF amyloid-ß 42 (Aß42), total (t)-tau, and phosphorylated (p)-tau concentrations were determined by enzyme-linked immunosorbent assays. Cognition was evaluated by the Mini-Mental State Examination (MMSE) and its domain scores. The associations of CSF biomarkers with cognitive measures were examined using regression models and the diagnostic value of CSF biomarkers was determined by receiver operating characteristics curves. Results: CSF Aß42 levels were lower, whereas t-tau/Aß42 and p-tau/Aß42 ratios were higher in patients with AD compared with those with FTD. Some MMSE domain scores were different in FTD and AD, but they did not improve the ability to distinguish between the two pathologies. Poor temporal orientation scores were associated with low Aß42 levels only in patients with FTD. The p-tau/Aß42 ratio reached sufficient levels of sensitivity and specificity to discriminate FTD with primary progressive aphasia from AD. Conclusions: The ratio of CSF p-tau/Aß42 is a sensitive and specific biomarker for discriminating patients with primary progressive aphasia from those with AD.

AB - Objective: This study aimed to determine the most appropriate cognitive and cerebrospinal fluid (CSF) biomarker setting to distinguish frontotemporal dementia (FTD) from Alzheimer’s disease (AD). Method: Patients with FTD, those with AD, and those without dementia were enrolled in this study. CSF amyloid-ß 42 (Aß42), total (t)-tau, and phosphorylated (p)-tau concentrations were determined by enzyme-linked immunosorbent assays. Cognition was evaluated by the Mini-Mental State Examination (MMSE) and its domain scores. The associations of CSF biomarkers with cognitive measures were examined using regression models and the diagnostic value of CSF biomarkers was determined by receiver operating characteristics curves. Results: CSF Aß42 levels were lower, whereas t-tau/Aß42 and p-tau/Aß42 ratios were higher in patients with AD compared with those with FTD. Some MMSE domain scores were different in FTD and AD, but they did not improve the ability to distinguish between the two pathologies. Poor temporal orientation scores were associated with low Aß42 levels only in patients with FTD. The p-tau/Aß42 ratio reached sufficient levels of sensitivity and specificity to discriminate FTD with primary progressive aphasia from AD. Conclusions: The ratio of CSF p-tau/Aß42 is a sensitive and specific biomarker for discriminating patients with primary progressive aphasia from those with AD.

KW - Alzheimer’s disease

KW - biomarker

KW - cerebrospinal fluid

KW - frontotemporal dementia

KW - Mini-Mental State Examination

KW - p-tau/Aß42 ratio

UR - http://www.scopus.com/inward/record.url?scp=85073663273&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85073663273&partnerID=8YFLogxK

U2 - 10.1177/0300060519860951

DO - 10.1177/0300060519860951

M3 - Article

C2 - 31524025

AN - SCOPUS:85073663273

VL - 47

SP - 4968

EP - 4980

JO - Journal of International Medical Research

JF - Journal of International Medical Research

SN - 0300-0605

IS - 10

ER -